InfuSystem Holdings, Inc
InfuSystem provides outpatient healthcare services and durable medical equipment to hospitals, oncology practices, ambulatory surgery centers and other healthcare providers. Headquartered in Rochester Hills, Michigan, it operates through two platforms: Patient Services and Device Solutions. Patient Services supplies ambulatory infusion pumps and disposable kits, coordinates delivery and payer billing, provides 24/7 nursing support, and handles equipment inspection, repair and certification. Its services also include wound care, pain management and pneumatic compression devices. Device Solutions sells or rents infusion pumps and other durable medical equipment, sells treatment consumables, and provides biomedical maintenance, repair and certification. InfuSystem earns money through third-party reimbursement for equipment use and supplies, direct sales and rentals, and fees for biomedical services. Its customer base includes oncology clinics, hospitals, home care and home infusion providers, skilled nursing facilities and pain centers.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $INFU in the last 30 days.
See all $INFU insider activity →InfuSystem Holdings (INFU) reaffirmed its 2026 pro forma revenue growth target of 6% to 8%, citing its scaling efforts in wound care. The company's outlook was shared in an AI-generated earnings call summary on Seeking Alpha.
InfuSystem reported a 22.9% TTM adjusted EBITDA margin, with $144.4M in TTM revenue and $33.1M in 2026 adjusted EBITDA. The company aims for a 22%-25% long-term margin range, citing ERP investments and billing efficiencies. Wound Care revenue grew 103% YoY in 2025. InfuSystem has $64.1M in liquidity and serves over 100,000 patients annually.
InfuSystem reported Q3 2026 revenue of $37.59M, up 3% YoY, and EPS of $0.15, up 36.4%. Patient Services revenue grew 15.4% due to higher treatment volume, while Device Solutions revenue declined 16.6%. Gross margin increased to 57.8%.
Over the past 7 days, AlphAI's AI scored 8 news stories mentioning INFU (InfuSystem Holdings, Inc). Coverage has skewed bullish: 5 bullish, 2 neutral, and 1 bearish.
Recent INFU coverage spans earnings, financial news and corporate actions.
Guidance unchanged; market may view reaffirmation as neutral to slightly negative if expectations were for an upgrade.
Guidance beat expectations, indicating stronger profitability and cash generation.
Earnings beat on both revenue and EPS; patient services growth offsets device segment decline.
Earnings beat and reaffirmed guidance suggest modest upside.
Earnings miss may trigger short-term sell pressure.
AlphAI scores every news story that mentions INFU with an AI model for sentiment and relevance, and aggregates insider trades from InfuSystem Holdings, Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
InfuSystem Holdings (INFU) reaffirmed its 2026 pro forma revenue growth target of 6% to 8%, citing its scaling efforts in wound care. The company's outlook was shared in an AI-generated earnings call summary on Seeking Alpha.
InfuSystem reported a 22.9% TTM adjusted EBITDA margin, with $144.4M in TTM revenue and $33.1M in 2026 adjusted EBITDA. The company aims for a 22%-25% long-term margin range, citing ERP investments and billing efficiencies. Wound Care revenue grew 103% YoY in 2025. InfuSystem has $64.1M in liquidity and serves over 100,000 patients annually.
InfuSystem reported Q3 2026 revenue of $37.59M, up 3% YoY, and EPS of $0.15, up 36.4%. Patient Services revenue grew 15.4% due to higher treatment volume, while Device Solutions revenue declined 16.6%. Gross margin increased to 57.8%.
InfuSystem Holdings, Inc (INFU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 (248) 291-1210 Contact: Barry Steele Chief Financial Officer (248) 260-2211 InfuSystem Announces Financial Results for Third Quarter 2026 Investor Conference Call to be held on November 10, 2026
InfuSystem Holdings (INFU) reported Q3 EPS of $0.12, missing estimates of $0.13. Revenue was $37.3M, slightly below the $37.39M consensus. The stock is up 2.48% over 3 months and 28% over 12 months, closing at $12.80. InvestingPro rates its financial health as 'great performance'.
InfuSystem Holdings, Inc (INFU) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Barry Steele Chief Financial Officer 248-260-2211 InfuSystem Announces Change in Third Quarter 2026 Earnings Release Date Rochester Hills, Michigan, No
InfuSystem Holdings (INFU) delays Q3 results to review software costs. The company, with its audit committee and accounting firm, is evaluating whether to capitalize or expense ERP system implementation costs totaling $4.2 million. INFU provides healthcare services, including oncology and pain management, and operates in the U.S. and Canada.
InfuSystem Holdings (INFU) will report Q3 2026 results on November 3 before market open. An investor call is scheduled for 9:00 a.m. ET the same day, with a replay available until February 3, 2027.
InfuSystem Holdings, Inc (INFU) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 FOR IMMEDIATE RELEASE CONTACT: Barry Steele Chief Financial Officer 248-260-2211 InfuSystem to Report Third Quarter 2026 Financial Results on November 3, 2026 Investor Conference Cal
Vaxcyte (PCVX) +31% on positive Phase 3 trial data, $500M stock offering. InfuSystem (INFU) +2% with Q2 revenue $36.9M, FY26 growth 6-8%. Illumina (ILMN) +7% with Q2 revenue $1.59B, FY26 guidance $4.6B-$4.64B. Charles River (CRL) +7% with Q2 revenue $1B, FY26 EPS up $0.25. HeartFlow (HTFL) +5% with Q2 revenue $64.1M, net loss $15.7M.
